Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial
Abstract
Purpose: To test whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure after hematopoietic stem cell transplantation (HSCT). Methods and Materials: A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT. Results: The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome. Conclusions: There is a trend in favor of captopril in mitigation of chronic renal failure after radiation-based HSCT.
- Authors:
-
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI (United States)
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI (United States)
- Department of Population Health, Medical College of Wisconsin, Milwaukee, WI (United States)
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI (United States)
- Publication Date:
- OSTI Identifier:
- 21124166
- Resource Type:
- Journal Article
- Journal Name:
- International Journal of Radiation Oncology, Biology and Physics
- Additional Journal Information:
- Journal Volume: 70; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2007.08.041; PII: S0360-3016(07)03992-2; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 62 RADIOLOGY AND NUCLEAR MEDICINE; ANGIOTENSIN; CREATININE; ENZYME INHIBITORS; FAILURES; KIDNEYS; STEM CELLS; WHOLE-BODY IRRADIATION
Citation Formats
Cohen, Eric P., Irving, Amy A. B.A., Drobyski, William R, Klein, John P, Passweg, Jakob, Talano, Julie-An M, Juckett, Mark B, and Moulder, John E. Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial. United States: N. p., 2008.
Web. doi:10.1016/j.ijrobp.2007.08.041.
Cohen, Eric P., Irving, Amy A. B.A., Drobyski, William R, Klein, John P, Passweg, Jakob, Talano, Julie-An M, Juckett, Mark B, & Moulder, John E. Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial. United States. https://doi.org/10.1016/j.ijrobp.2007.08.041
Cohen, Eric P., Irving, Amy A. B.A., Drobyski, William R, Klein, John P, Passweg, Jakob, Talano, Julie-An M, Juckett, Mark B, and Moulder, John E. 2008.
"Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial". United States. https://doi.org/10.1016/j.ijrobp.2007.08.041.
@article{osti_21124166,
title = {Captopril to Mitigate Chronic Renal Failure After Hematopoietic Stem Cell Transplantation: A Randomized Controlled Trial},
author = {Cohen, Eric P. and Irving, Amy A. B.A. and Drobyski, William R and Klein, John P and Passweg, Jakob and Talano, Julie-An M and Juckett, Mark B and Moulder, John E},
abstractNote = {Purpose: To test whether the angiotensin-converting enzyme inhibitor captopril was effective in mitigating chronic renal failure after hematopoietic stem cell transplantation (HSCT). Methods and Materials: A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT. Results: The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome. Conclusions: There is a trend in favor of captopril in mitigation of chronic renal failure after radiation-based HSCT.},
doi = {10.1016/j.ijrobp.2007.08.041},
url = {https://www.osti.gov/biblio/21124166},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 70,
place = {United States},
year = {Tue Apr 01 00:00:00 EDT 2008},
month = {Tue Apr 01 00:00:00 EDT 2008}
}